Automated CAR T Cell Manufacturing with CliniMACS Prodigy

Added:

In Vivo CAR T-Cell Generation: Bypassing Ex Vivo Manufacturing

While automated platforms like the CliniMACS Prodigy significantly improve the efficiency of ex vivo (outside the body) CAR T-cell manufacturing, a major opposing paradigm argues that the future of cell therapy lies in in vivo (inside the body) cell programming. Ex vivo manufacturing, even when automated, remains highly expensive, logistically complex, and requires a lengthy "vein-to-vein" waiting period during which a patient's disease can progress. In contrast, the in vivo approach delivers genetic engineering tools (such as mRNA-carrying lipid nanoparticles or viral vectors) directly into the patient's bloodstream to reprogram T cells internally. By entirely eliminating the need for cell harvesting, cleanrooms, and dedicated manufacturing hardware like the CliniMACS Prodigy, in vivo CAR T therapy offers a potentially safer, instantly available, and vastly cheaper alternative that could democratize access to these life-saving therapeutics.

Fundamental concepts of immunology and T-cell biology, including antigen recognition and T-cell activation.
The basic mechanism of Chimeric Antigen Receptor (CAR) T-cell therapy, including gene transduction and target antigens.
Standard phases of cell therapy manufacturing: isolation, activation, transduction, expansion, and formulation.
Good Manufacturing Practice (GMP) guidelines and the importance of maintaining sterility and contamination control in clinical bioprocessing.
Quality Control (QC) and release testing protocols for CAR T-cell products, such as assessing cell viability, purity, and transduction efficiency.
Decentralized versus centralized manufacturing models and the logistical challenges of scaling out autologous therapies.
Advanced gene-editing tools (such as CRISPR-Cas9) integrated into automated cell manufacturing systems for next-generation CAR-T therapies.
The clinical and commercial logistics of cell therapies, including vein-to-vein chain of custody and cryogenic transport.
42.4K views313likes5:01@Miltenyi_BiotecOriginal Release: 2019-02-04

The CliniMACS Prodigy T Cell Transduction Process enables fully automated clinical-grade CAR T cell manufacturing through a closed-system workflow that includes cell enrichment via magnetic separation, activation, lentiviral transduction to introduce chimeric antigen receptors, and controlled expansion with media exchanges, ultimately producing therapeutic T cells in approximately 10-14 days.